T

he immune system constantly scans the body for tumor cells, destroying most of them before they can become a detectable cancer, but sometimes it needs a boost. That’s the thinking behind the new generation of cancer treatments called immunotherapies. One of the most promising versions are CAR-Ts (chimeric antigen receptor T cells).

Two CAR-Ts have been approved by the Food and Drug Administration: Yescarta, developed Kite Pharma (which was bought by Gilead), is used to treat adult patients with certain types of large B-cell lymphoma, and Kymriah, from Novartis, is for a form of acute lymphoblastic leukemia.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • I am a big fan of Sharon Begley. I try to read everything by her that I come across. But – subscribe to Stat Plus would just add more emails that I don’t have time to read. I read Megan five days a week, and I often read articles she recommends, but I also read a great many other things and Medicine is not my primary interest. Please don’t do this again. I know you want in increase Stat Plus’ members but please understand that everyone’s time is limited.
    Thank you,
    Norma Frank

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy